Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab and Tofacitinib in Vascular Behçet's Syndrome
NCT05845723Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab and tofacitinib in Behçet syndrome (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete Remission Rate at 12 weeks. Started Jun 2023; status: recruiting.
02
Drugs
tocilizumabtofacitinib
03
Conditions
Behçet syndrome
Beyond the preview
Go deeper on NCT05845723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845723.